Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients

A sharp fluctuation in peripheral blood cells shortly after dasatinib administration

(2012) Jun Imagawa et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation

(2011) A Kreutzman et al.   LEUKEMIA

A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors

(2011) John J. Powers et al.   LEUKEMIA & LYMPHOMA

Dasatinib, an immunomodulator?

(2010) F. Ravandi   BLOOD

Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy

(2010) A. Kreutzman et al.   BLOOD

Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy

(2010) Peter Rohon et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion

(2010) Yasunobu Nagata et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling

(2010) J. Chen et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

(2010) E Jabbour et al.   LEUKEMIA

Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib

(2010) Jason N. Valent et al.   LEUKEMIA RESEARCH

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion

(2009) Kimmo Porkka et al.   CANCER

Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily

(2009) C. Sillaber et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

(2009) S Mustjoki et al.   LEUKEMIA

Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis

(2008) Hugues de Lavallade et al.   BRITISH JOURNAL OF HAEMATOLOGY

Profound Inhibition of Antigen-Specific T-Cell Effector Functions by Dasatinib

(2008) R. Weichsel et al.   CLINICAL CANCER RESEARCH

Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo

(2008) Cara K. Fraser et al.   EXPERIMENTAL HEMATOLOGY

Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia

(2008) D. H. Kim et al.   HAEMATOLOGICA